by Mike Splaine In late April, I will join with hundreds of advocates for the Alzheimer’s Association 25th annual public policy forum and make Congressional visits with persons with dementia, family and professional caregivers and others who make up the faces of a broadening movement. I have done this many times but a milestone year — […]
Forty-seven LEAD Coalition member organizations and supporters joined together to submit formal comment welcoming the U.S. Food and Drug Administration (FDA) draft guidance which outlines FDA’s current thinking as to how to a drug developer may demonstrate efficacy in clinical trials in patients in the early stages of Alzheimer’s disease that occur before the onset of overt dementia. Read more…
The LEAD March newsletter has been posted. View it online here. Subscribe to the newsletter here.
LEAD Coalition Executive Director Ian Kremer wrote to the National Institute on Aging to propose a range of specific actions and to call for genuine, candid, persistent, inclusive collaboration by all stakeholders. Read more…
As U.S. Health and Human Services Secretary Sebelius develops the annual update for the National Plan to Address Alzheimer’s Disease, 54 LEAD Coalition member and partner organizations have joined together to offer recommendations for strengthening the Plan.
The LEAD February newsletter has been posted. View it online here. Subscribe to the newsletter here.
Accelerating Alzheimer’s Research & Drug Discovery Through a National Institutional Review Board for Neurodegenerative Diseases.
LEAD is rallying a diverse and growing national coalition insisting that Congress do more, not less, to stand up for Americans facing Alzheimer’s disease and related disorders.
The LEAD January Newsletter has been posted. View it online here. Subscribe to the newsletter here.
The LEAD December Newsletter has been posted. View it online here. Subscribe to the newsletter here.